Biosimilars for the treatment of psoriasis: a narrative review

The introduction of systemic biologic therapies marked a significant advancement in the treatment of moderate to severe psoriasis. However, the high cost associated with these treatments has considerably restricted their widespread utilization. The expiration of biologic patents has allowed the development of biosimilars - medications that are highly similar to approved biologics. Biosimilars hold the promise of reducing treatment costs, thereby enhancing patient access to biologic therapies and contributing to the sustainability of healthcare spending. Nonetheless, the unique regulatory pathways for biosimilars introduce uncertainties regarding their application in real-world psoriasis care. Adoption and regulation of biosimilars differ considerably across countries, reflecting diverse approaches and priorities within global healthcare systems. Potential variations between biosimilars and their originator biologics raise questions about their comparative effectiveness and safety. Current evidence supporting biosimilars for psoriasis treatment is largely based on a limited number of randomized controlled trials (RCTs), with a notable lack of robust real-world evidence. As more biosimilars enter the market, evaluating their use in real-world settings is crucial to identify any differences in effectiveness and safety compared to originators or to enhance their uptake by improving the perceptions of physicians and patients. This review explores the opportunities and challenges presented by biosimilars and underscores the existing gaps in evidence regarding their use in psoriasis treatment.